Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabinovich, Emma, Pradhan, Kith, Sica, R. Alejandro, Bachier-Rodriguez, Lizamarie, Mantzaris, Ioannis, Kornblum, Noah, Shastri, Aditi, Gritsman, Kira, Goldfinger, Mendel, Verma, Amit, Braunschweig, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656085/
https://www.ncbi.nlm.nih.gov/pubmed/34886908
http://dx.doi.org/10.1186/s40164-021-00248-9
_version_ 1784612210746589184
author Rabinovich, Emma
Pradhan, Kith
Sica, R. Alejandro
Bachier-Rodriguez, Lizamarie
Mantzaris, Ioannis
Kornblum, Noah
Shastri, Aditi
Gritsman, Kira
Goldfinger, Mendel
Verma, Amit
Braunschweig, Ira
author_facet Rabinovich, Emma
Pradhan, Kith
Sica, R. Alejandro
Bachier-Rodriguez, Lizamarie
Mantzaris, Ioannis
Kornblum, Noah
Shastri, Aditi
Gritsman, Kira
Goldfinger, Mendel
Verma, Amit
Braunschweig, Ira
author_sort Rabinovich, Emma
collection PubMed
description Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers.
format Online
Article
Text
id pubmed-8656085
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86560852021-12-10 Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort Rabinovich, Emma Pradhan, Kith Sica, R. Alejandro Bachier-Rodriguez, Lizamarie Mantzaris, Ioannis Kornblum, Noah Shastri, Aditi Gritsman, Kira Goldfinger, Mendel Verma, Amit Braunschweig, Ira Exp Hematol Oncol Letter to the Editor Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers. BioMed Central 2021-12-09 /pmc/articles/PMC8656085/ /pubmed/34886908 http://dx.doi.org/10.1186/s40164-021-00248-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Rabinovich, Emma
Pradhan, Kith
Sica, R. Alejandro
Bachier-Rodriguez, Lizamarie
Mantzaris, Ioannis
Kornblum, Noah
Shastri, Aditi
Gritsman, Kira
Goldfinger, Mendel
Verma, Amit
Braunschweig, Ira
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
title Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
title_full Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
title_fullStr Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
title_full_unstemmed Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
title_short Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
title_sort elevated ldh greater than 400 u/l portends poorer overall survival in diffuse large b-cell lymphoma patients treated with cd19 car-t cell therapy in a real world multi-ethnic cohort
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656085/
https://www.ncbi.nlm.nih.gov/pubmed/34886908
http://dx.doi.org/10.1186/s40164-021-00248-9
work_keys_str_mv AT rabinovichemma elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT pradhankith elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT sicaralejandro elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT bachierrodriguezlizamarie elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT mantzarisioannis elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT kornblumnoah elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT shastriaditi elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT gritsmankira elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT goldfingermendel elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT vermaamit elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort
AT braunschweigira elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort

Ejemplares similares